Sign in

CIK 0001321834

  • Non-accelerated filer
  • Smaller reporting company

Q/C TECHNOLOGIES, INC.

Sign in to watch
Ticker
QCLS
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 856-848-8698
Business address
1185 AVENUE OF THE AMERICAS, SUITE 249, NEW YORK, NY, 10036
Former names
Q/C TECHNOLOGIES, INC., TNF Pharmaceuticals, Inc., MyMD Pharmaceuticals, Inc., Akers Biosciences, Inc., Akers Biosciences Inc
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-11-18 PharmaCyte Biotech, Inc. 10% owner Option exercise +4,982,272 5,152,000
2026-11-18 PharmaCyte Biotech, Inc. 10% owner Option exercise · Series G Long-Term Warrants −851,304 13,318,344
2026-11-18 PharmaCyte Biotech, Inc. 10% owner Other acquisition · Series H Convertible Preferred Stock +3,000 3,000
2025-11-14 PharmaCyte Biotech, Inc. 10% owner Purchase · Warrants +889,865 889,865
2025-09-04 PharmaCyte Biotech, Inc. 10% owner Purchase · Series H Convertible Preferred Stock +889,865 889,865

Page 1 of 1 · 5 trades